Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 3, 2013, Pages 393-405

  Shadab, M D ^a   Khan, Rashid A ^a   Mustafa, Gulam ^a   Chuttani, Krishna ^b   Baboota, Sanjula ^a   Sahni, Jasjeet K ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Biodistribution study; Bromocriptine; Chitosan; Haloperidol; Nanoparticles; Parkinson disease

Indexed keywords

BROMOCRIPTINE; CHITOSAN; HALOPERIDOL; NANOPARTICLE; TECHNETIUM 99M; ANTIPARKINSON AGENT; PERTECHNETIC ACID TC 99M;

AKINESIA; ANIMAL MODEL; ARTICLE; BEHAVIOR; BLOOD BRAIN BARRIER; CATALEPSY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; GAMMA SCINTIGRAPHY; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; HYPOKINESIA; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOPHYSIOLOGY; RANDOMIZATION; SCINTISCANNING; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; BROMOCRIPTINE; CATALEPSY; CHITOSAN; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HYPOKINESIA; INJECTIONS, INTRAVENOUS; MALE; MICE; NANOPARTICLES; NEURONS; PARKINSON DISEASE; RANDOM ALLOCATION; SODIUM PERTECHNETATE TC 99M; TISSUE DISTRIBUTION;

EID: 84872412539     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.12.007     Document Type: Article

References (40)

1. Babbar, A.K., Singh, K., Goel, H.C., Chauhan, U.S., Sharma, R.K., 2000. Evaluation of 99mTc labeled Photosan-3, a heamatoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy. Nucl. Med. Biol. 27, 419-426.
2. Chen, L. et al., 2008. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28 (2), 425-433.
3. Cho, K., Wang, X., Nie, S., Chen, Z., Shin, D.M., 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer. Res. 14, 1310-1316.
4. Degim, I.T., Acartürk, F., Erdogan, D., Lortlar, N.D., 2003. Transdermal administration of bromocriptine. Biol. Pharm. Bull. 26 (4), 501-505.
5. Dhuria, S.V., Hanson, L.R., Frey, W.H., 2010. Intranasal delivery to the central nervous system: Mechanism and experimental considerations. J. Pharm. Sci. 99 (4), 1654-1673.
6. Esposito, E. et al., 2012. Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study. Eur. J. Pharm. Biopharm. 80 (2), 306-314.
7. Fan, W., Yan, W., Xu, Z., Ni, H., 2012. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf. B 90, 21-27.
8. Fernández, M., Negro, S., Slowing, K., Fernández- Carballido, A., Barcia, E., 2011. An effective novel delivery strategy of rasagiline for Parkinson's disease. Int. J. Pharm. 419, 271-280.
9. Fernandez-Urrusuno, R., Romani, D., Calvo, P., 1999. Development of a freeze dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. STP. Pharm. Sci. 5, 429-436.
10. Gao et al., 2007. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm. 340, 207-215.
11. Graff, C.L., Pollack, G.M., 2005. Nasal drug administration: Potential for targeted central nervous system delivery. J. Pharm. Sci. 94, 1187-1195.
12. Granveau-Renouf, S., Valente, D., Durocher, A., Grognet, J.M., Ezan, E., 2000. Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum. Eur. J. Drug. Metab. Pharmacokinet. 25, 79-84.
13. Jingou, J., Shilei, H., Weiqi, L., Danjun, W., Tengfei, W., Yi, X., 2011. Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids Surf. B 83, 103-107.
14. Khan, S., Patil, K., Bobade, N., Yeole, P., Gaikwad, R., 2010. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J. Drug. Target 18, 223-234.
15. Kumar, M., Misra, A., Babbar, A.K., Mishra, A.K., Mishra, P., Pathak, K., 2008a. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 358, 285-291.
16. Kumar, M., Misra, A., Mishra, A.K., Mishra, P., Pathak, K., 2008b. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug. Target. 16, 806-814.
17. Lim, J.H. et al., 2009. Protective effect of bromocriptine against BH4-induced Cath. a cell death involving up-regulation of antioxidant enzymes. Neurosci. Lett. 451, 185-189.
18. Lowary, O.H., Rosebrough, N.J., Farr, A.L., 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
19. Luthra, P.M., Barodia, S.K., Raghubir, R., 2009. Antagonism of haloperidol-induced swim impairment in l-dopa and caffeine treated mice. A pre-clinical model to study Parkinson's disease. J. Neurosci. Methods 178, 284-290.
20. Md, S., Kumar, M., Baboota, S., Sahni, J.K., Ali, J. Preparation, Characterization and Evaluation of Bromocriptine Loaded Chitosan Nanoparticles for Intranasal Delivery Sci. Adv. Mater. 4 (9), 961-965.
21. Mistry, A., Stolnik, S., Illum, L., 2009. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 379, 146-157.
22. Müller, R.H., 1991. Colloidal Carriers for Controlled Drug Delivery and Targeting. CRC Press, Boca Raton.
23. Muller, R.H., Jacobs, C., Kayser, O., 2001. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 47, 3-19.
24. Ohkawa, H., Ohishi, N., Yagi, K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 359-364.
25. Papadimitriou, S., Bikiaris, D., Avgoustakis, K., Karavas, E., Georgarakis, M., 2008. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohyd. Polym. 73, 44-54.
26. Reddy, L., Sharma, R., Chuttani, K., Mishra, A., Murthy, R., 2004. Etoposideincorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 6 (3), 23.
27. Schapira, A.H.V., 2005. Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 76, 1472-1478.
28. Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein bound and nonprotein sulfhydryl group in tissue with Ellman's reagent. Anal. Biochem. 25, 192-205.
29. Seju, U., Kumar, A., Sawant, K.K., 2011. Development and evaluation of olanzapineloaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta. Biomater. 7, 4169-4176.
30. Trapani, A. et al., 2011. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int. J. Pharm. 419, 296-307.
31. Trevitt, J., Vallance, C., Harris, A., Goode, T., 2009. Adenosine antagonists reverse the cataleptic effects of haloperidol: Implications for the treatment of Parkinson's disease. Pharmacol. Biochem. Behav. 925, 21-527.
32. Tsai, Y.M., Chien, C.F., Lin, L.C., Tsai, T.H., 2011. Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. Int. J. Pharm. 416, 331-338.
33. Vautier, S. et al., 2006. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur. J. Pharm. Sci. 2 (7), 167-174.
34. Verma, R., Nehru, B., 2009. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem. Int. 55, 369-375.
35. Vyas, T.K., Shahiwala, A., Marathe, S., Misra, A., 2005. Intranasal drug delivery for brain targeting. Curr. Drug. Deliv. 2, 165-175.
36. Wang, F., Jiang, X., Lu, W., 2003. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int. J. Pharm. 263, 1-7.
37. Wang, X., Chi, N., Tang, X., 2008. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur. J. Pharm. Biopharm. 70, 735-740.
38. Wen, Z. et al., 2011. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J. Control. Release 151, 131-138.
39. Yin, Y., Chen, D., Qiao, M., Lu, Z., Hu, H., 2006. Preparation and evaluation of lectinconjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release 116, 337.
40. Zhang, Q., Jiang, X., Jiang, W., Lu, W., Su, L., Shi, Z., 2004. Preparation of nimodipine loaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int. J. Pharm. 275, 85-96.